Layoff
Oct 2022Lucira announced cost-reduction plans and workforce reductions in 2022; later reporting said the combined reductions in force amounted to roughly 68% of the workforce.
SourceNext generation infectious disease test kits
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Lucira Health was an Emeryville-based medical diagnostics company that pioneered single-use molecular infectious-disease testing, starting with an at-home COVID-19 test and later a combined COVID-19/flu test. The business went public in 2021, filed Chapter 11 in 2023, and was acquired by Pfizer; the branded product now appears as LUCIRA by Pfizer.
Primary product
LUCIRA® by Pfizer COVID-19 & Flu Home Test
Founded
2013
Headquarters
1412 62nd Street, Emeryville, California 94608
Team size
11-50
Industry
Medical Equipment Manufacturing
Sub-industry
Molecular infectious disease diagnostics
Offices
1412 62nd Street, Emeryville, California 94608
Business model
direct-to-consumer OTC retail
point-of-care B2B diagnostics
provider and distributor sales
retail e-commerce distribution
telehealth-enabled test-to-treat
Funding
Stage
public (pre-acquisition)
Total raised
$256M
Latest round
debt financing · Nov 2022
Latest amount
$30M
Debt financing (first tranche)
Nov 2022
Feb 2021 · public investors
Convertible notes (2020B notes)
Dec 2020 · existing investors
Aug 2019 · Seraph Group
Oct 2015
Nov 2014
People & investors
Leadership
President & CEO
Vice President Strategy and Business Development
Senior Vice President, Digital Solutions
Senior Director of Market Access
Director of Analytics
Founders
Co-founder and Chief Technology Officer
Co-founder
Co-founder, Founding CEO & Board Member
Work & culture
Mission-driven and fast-moving, with a strong emphasis on accessible diagnostics, consumer-friendly design, and rapid response to respiratory-disease demand. Public messaging emphasized innovation, lab-quality testing at home, and test-to-treat workflows.
Visa sponsorship
Yes
Compensation
Executive offers disclosed base salaries around $310k-$410k, a 40% target annual bonus, a $170k sign-on/retention payment for one executive role, and RSU grants around $1.5M; H1B wage filings show technical roles in roughly the $74.8k-$150k range.
Benefits
health insurance
dental insurance
vision insurance
annual discretionary bonus
sign-on/retention bonus
officer severance plan
expense reimbursement
Product & market
Pricing
Single-use per-test pricing with separate OTC retail, provider, and distributor channels; public pricing disclosures included a $75 consumer kit, a $89 list price with coupon on Amazon, and a provider list price of $83.90 on Pfizer Prime for 24-unit orders.
Differentiators
- —single-use molecular test with no separate reader
- —palm-sized, battery-powered format
- —PCR-quality / lab-quality molecular results
- —results in about 30 minutes
- —OTC at-home and point-of-care use
- —2-in-1 COVID-19 and flu A/B testing
- —LUCI PASS digital result reporting
- —no calibration or maintenance required
Technology
Snowflake
Informatica
Tableau
Amazon S3
Cloudflare CDN
OneTrust
Adobe Tag Manager
Open Graph
Customers
consumers
healthcare providers
hospital networks and IDNs
corporate employers
senior living facilities
telehealth partners
retail buyers
distributors
international customers
travel and leisure customers
Competitors
Cue Health
Visby Medical
Abbott
Ellume
OraSure Technologies
Quidel
Sherlock Biosciences
Sense Biodetection
Scale & contact
Estimated revenue
$90M-$100M
Signals & risks
Other
Feb 2023Lucira filed for Chapter 11 bankruptcy protection and said it would pursue a strategic sale while continuing operations.
SourceAcquisition
Apr 2023Pfizer acquired Lucira Health assets through a bankruptcy auction for approximately $36.4 million, with the asset sale closing on April 20, 2023.
SourceShutdown
Feb 2025Pfizer decided to shut down the Lucira Health business by the end of Q1 2025, ending manufacturing, sale, and promotion of the Lucira molecular COVID/flu tests.
SourceOther
Oct 2025FDA revoked the EUAs for the Lucira by Pfizer COVID-19 & Flu Test and Home Test at Pfizer's request after no viable reagents remained in U.S. distribution.
SourceLatest news
Federal Register · Jan 2026
FDA revoked the Lucira by Pfizer EUAs effective Oct. 22, 2025, at Pfizer's request after the company said no viable reagents remained in U.S. distribution.
360Dx · Feb 2025
Pfizer decided to stop manufacturing, selling, and promoting the Lucira line after acquiring the business in 2023.
GenomeWeb · Apr 2023
Lucira said Pfizer won the bankruptcy auction and the asset sale closed on April 20, 2023.
Healthcare Dive · Feb 2023
FDA authorized Lucira's at-home COVID/flu combo test days after the company filed Chapter 11, highlighting the long approval cycle and the company's financial distress.
Pfizer/Lucira notice
Pfizer published a consumer and HCP notification about some lots containing swabs that expired earlier than the kit's printed expiration date; impacted kits expired between Feb. and June 2025.
Jobs and careers at Lucira Health
0 jobs at Lucira Health
No open positions
Check back later for new openings